基于细胞的治疗和组织工程是肝移植治疗终末期肝病的有希望的替代品。然而,健康和功能性细胞的来源有限以及植入率低是基于细胞的治疗方法面临的主要挑战.另一方面,生物工程组织的生产可行性和大小是组织工程的主要瓶颈。这里,我们通过移植天然的生物工程支架诱导再生大鼠纤维化肝模型与自体干/祖细胞的天然微环境。在主要实验组中,将来自脱细胞肝脏细胞外基质(LEM)的1mm3基质衍生因子-1α(SDF-1α;S)负载支架移植(Tx)到纤维化肝脏中,并通过粒细胞集落刺激因子(G-CSF;G)疗法动员内源性干/祖细胞。移植后四周,肝纤维化和坏死的变化,细胞移植和分化的功效,血管生成,和肝功能恢复评估(LEM-TxSG)组,并与其他组进行比较。我们发现LEM-TxSG的肝纤维化阶段显着减少,与对照(纤维化)组相比,LEM-TxS和LEM-TxG组。肝坏死分级,与对照组相比,所有实验组的丙氨酸转氨酶(ALT)和天冬氨酸转氨酶(AST)水平显著降低。然而,与LEM-Tx相比,LEM-TxSG组移植到移植支架中的细胞数量和白蛋白(Alb)阳性细胞/总掺入细胞的比例明显更高,LEM-TxS和LEM-TxG组。LEM-Tx中血清Alb水平升高,LEM-TxS,和LEM-TxG组,在LEM-TxSG组中最高,明显高于纤维化组。LEM-TxSG组的小血管形成显著高于LEM-Tx和LEM-TxS组。完全正确,这些发现支持体内组织工程方法作为肝纤维化的一种可能的新型治疗策略的应用。
Cell-based therapy and tissue engineering are promising substitutes for liver transplantation to cure end-stage liver disorders. However, the limited sources for healthy and functional cells and poor engraftment rate are main challenges to the cell-based therapy approach. On the other hand, feasibility of production and size of bioengineered tissues are primary bottlenecks in tissue engineering. Here, we induce regeneration in a rat fibrotic liver model by transplanting a natural bioengineered scaffold with a native microenvironment repopulated with autologous stem/progenitor cells. In the main experimental group, a 1 mm3 stromal derived factor-1α (SDF-1α; S) loaded scaffold from decellularized liver extracellular matrix (LEM) was transplanted (Tx) into a fibrotic liver and the endogenous stem/progenitor cells were mobilized via granulocyte colony stimulating factor (G-CSF; G) therapy. Four weeks after transplantation, changes in liver fibrosis and necrosis, efficacy of cell engraftment and differentiation, vasculogenesis, and liver function recovery were assessed in this (LEM-TxSG) group and compared to the other groups. We found significant reduction in liver fibrosis stage in the LEM-TxSG, LEM-TxS and LEM-TxG groups compared to the control (fibrotic) group. Liver necrosis grade, and alanine transaminase (ALT) and aspartate transaminase (AST) levels dramatically reduced in all experimental groups compared to the control group. However, the number of engrafted cells into the transplanted scaffold and ratio of albumin (Alb) positive cells per total incorporated cells were considerably higher in the LEM-TxSG group compared to the LEM-Tx, LEM-TxS and LEM-TxG groups. Serum Alb levels increased in the LEM-Tx, LEM-TxS, and LEM-TxG groups, and was highest in the LEM-TxSG group, which was significantly more than the fibrotic group. Small vessel formation in the LEM-TxSG group was significantly higher than the LEM-Tx and LEM-TxS groups. Totally, these findings support application of the in vivo tissue engineering approach as a possible novel therapeutic strategy for liver fibrosis.